CompletedNot Applicable

Extracellular Matrix Marker of Arrhythmia Risk (EMMA)

United States63 participantsStarted 2006-09

Plain-language summary

Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * LVEF of ≤ 35% measured within 6 months of ICD implantation * NYHA class II-IV at the time of ICD implantation * ICD implantation at least 1 year prior to enrollment Exclusion Criteria: * Status post heart transplant * Known malignancy in the past 2 years. * Recent procedure, intervention or surgery within the past 90 days * Acute MI, CABG, or PTCA/stent within the past 2 months. * Active rheumatoid arthritis or pulmonary or hepatic fibrosis. * Taking chronic steroid therapy for a medical condition * Currently pregnant * Enrolled in a concurrent study that may confound the results of this study

What they're measuring

MMP-2

Timeframe: At time of enrollment

MMP-9

Timeframe: At time of enrollment

Trial details

NCT IDNCT00376532

SponsorThomas Jefferson University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2008-09

Results submitted2014-05-05

View on ClinicalTrials.gov More Myocardiopathies trials